Below are two new clinical trials for breast and lung cancer. Read more about each clinical study being offered at the Johns Hopkins Kimmel Cancer Center and the criteria for eligible participants.
New clinical trial for melanoma patients with newly diagnosed metastases to the brain or spine tests the combination of a drug, called ipilimumab, which targets the immune system, and stereotactic radiosurgery, a precise type of radiation therapy.
A clinical trial for rectal cancer patients will test a technique that delivers high doses of radiation directly to rectal tumors.
The study will evaluate the effectiveness of endorectal brachytherapy (EBT) in patients with stage II and III low rectal cancers, with tumors less than 12 centimeters from the anus.
A new clinical trial for breast cancer patients will test the effects of two drugs, called 5-Azacitidine (5-AZA) and Entinostat. Preliminary results from clinical trials at Johns Hopkins in cancers other than breast cancer indicate that this combination is safe and tolerable and associated with improved outcome for certain patients. The drugs are believed to work by targeting specific changes that occur in important breast cancer genes.
Epigenetic Therapy for Patients with Surgically Resected Early Stage Lung Cancer
Traditionally, patients with early stage lung cancer have been monitored with CT screenings to see if the cancer returns, there have been no additional treatment options for surgery. Now, at Johns Hopkins, there is a new therapy that is being investigated for patients after surgery. This new treatment utilizes epigenetic therapy in the treatment of early stage lung cancer.